中轴型脊柱关节炎患者纤维肌痛状态变化:BSRBR-AS登记研究
基于英国风湿病学会生物制剂登记中轴型脊柱关节炎队列(BSRBR-AS)的前瞻性研究,纳入801例有至少两次随访的患者,分析纤维肌痛(FM)发生与缓解的预测因素。多变量模型显示,基线高BASDAI和广泛疼痛指数(WPI)与FM发生相关;低BASFI、低WPI及开始TNF抑制剂与FM缓解相关。
要点
- 基线高BASDAI与高WPI是中轴型脊柱关节炎患者发生纤维肌痛的预测因素。
- 基线低BASFI、低WPI及开始TNF抑制剂与纤维肌痛缓解相关。
- 对持续高疾病活动度和广泛疼痛的中轴型脊柱关节炎患者应考虑共病纤维肌痛。
核心结论
- 高疾病活动度和广泛疼痛与中轴型脊柱关节炎患者纤维肌痛的发生相关。
- 低BASFI、低WPI及开始TNF抑制剂与纤维肌痛缓解相关。
研究设计与样本
- 英国风湿病学会生物制剂登记中轴型脊柱关节炎前瞻性研究(BSRBR-AS),从83个中心招募患者。
- 纤维肌痛采用2015年自报纤维肌痛调查诊断标准诊断。
- 共801例有两次及以上随访的患者纳入分析,其中女性247例(30.8%)。
主要发现
- 基线无纤维肌痛的686例中,随访期间45例发生纤维肌痛。
- 基线有纤维肌痛的115例中,随访期间77例缓解。
- 最终多变量模型中,基线高BASDAI [OR 1.27(95%CI 1.08,1.49)]和高WPI [OR 1.14(95%CI 1.02,1.28)]与纤维肌痛发生显著相关。
- 基线低BASFI [OR 0.68(95%CI 0.53,0.86)]和低WPI [OR 0.84(95%CI 0.720,0.97)]及开始TNF抑制剂 [OR 3.86(95%CI 1.54,9.71)]与纤维肌痛缓解显著相关。
关键数值与推荐
- 纤维肌痛诊断采用2015年自报纤维肌痛调查诊断标准。
- BASDAI每升高1单位,纤维肌痛发生风险OR为1.27(95%CI 1.08,1.49)。
- WPI每升高1单位,纤维肌痛发生风险OR为1.14(95%CI 1.02,1.28)。
- BASFI每升高1单位,纤维肌痛缓解风险OR为0.68(95%CI 0.53,0.86)。
- 开始TNF抑制剂与纤维肌痛缓解的OR为3.86(95%CI 1.54,9.71)。
临床怎么用
- 对中轴型脊柱关节炎患者应评估纤维肌痛共病,尤其存在持续高疾病活动度和广泛疼痛时。
- 低BASFI和低WPI提示纤维肌痛更可能缓解。
- 开始TNF抑制剂与纤维肌痛缓解相关,但需结合疾病活动度综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify factors associated with FM development and recovery in patients with axial SpA (axSpA). METHODS: The British Society of Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS) recruited patients with axSpA from 83 centres in a prospective study. FM was diagnosed using the self-reported Fibromyalgia Survey Diagnostic Criteria from 2015. Measures of axSpA disease activity and clinical findings were recorded at regular intervals. We identified predictors for FM development and recovery between yearly visits using uni- and multivariable logistic regression models. RESULTS: A total of 801 participants, 247 (30.8%) female, had two or more visits and were eligible for inclusion. A total of 686 participants did not have FM at baseline, of whom 45 had developed FM at follow-up, while 115 participants had FM at baseline, of whom 77 had recovered at follow-up. A high baseline BASDAI score [odds ratio (OR) 1.27 (95% CI 1.08, 1.49)] and Widespread Pain Index (WPI) [OR 1.14 (95% CI 1.02, 1.28)] were significantly associated with FM development in the final multivariable model. A low baseline BASFI score [OR 0.68 (95% CI 0.53, 0.86)] and WPI [OR 0.84 (95% CI 0.720, 0.97)] and starting a TNF inhibitor [OR 3.86 (95% CI 1.54, 9.71)] were significantly associated with FM recovery. CONCLUSION: High levels of disease activity and the presence of widespread pain is associated with the development of FM in patients with axSpA, while low levels of the same variables and starting a TNF inhibitor are associated with recovery from FM. The presence of comorbid FM should be considered in patients with persistent high axSpA disease activity and widespread pain.
引用
- Provan SA, Dean LE, Jones GT, et al. The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis. Rheumatology (Oxford). 2021. PMID: 34469570. doi:10.1093/rheumatology/keaa888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。